Product Description
Hanmi Company Limited is developing hcp-1102, an Oral agent for Asthma With Allergic Rhinitis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02552667)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hanmi
Company Location: LOS ANGELES CA 90010
Company CEO: Bonita I. Lee
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Rhinitis, Allergic, Perennial|Rhinitis, Allergic|Asthma, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04324918 |
HM-MOLZ-303 | P3 |
Completed |
Rhinitis, Allergic, Perennial |
2019-06-24 |
2020-03-29 |
Primary Endpoints|Treatments |
|
NCT02552667 |
HM-MOLZ-302 | P3 |
Completed |
Rhinitis, Allergic|Asthma, Allergic |
2015-07-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|